?

Vectura to Present at the 31st Annual J.P. Morgan Healthcare Conference

Chippenham, UK - 07 January 2013:Vectura Group plc ("Vectura"; LSE: VEC)announced today that Dr Chris Blackwell, Vectura's Chief Executive Officer, is scheduled to present at the 31st Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2013, at 08:30 a.m. PST. The conference will be held from January 7-10, 2013 at the Westin St. Francis Hotel in San Francisco, CA.

The presentation will be webcast live and can be reached from Vectura's web site at http://www.vectura.com/investors/reports/2013.aspx. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.

-Ends-

Enquiries

Vectura Group plc

+44 (0)1249 667700

Chris Blackwell, Chief Executive


Karl Keegan, Corporate Development Director




FTI Consulting

+44 (0)20 7831 3113

Ben Atwell


Simon Conway


Susan Stuart


About Vectura

Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn.

Vectura has six products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK).

Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy. For further information, please visit Vectura's website atwww.vectura.com.

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


This information is provided by RNS
The company news service from the London Stock Exchange
ENDNRANKADDKBKBCDK
distributed by